Stefan Cross - Mayne Pharma President of Mayne Pharma USA
| MAYNF Stock | USD 3.10 0.10 3.33% |
President
Mr. Stefan Cross is President International Operations of the company. He brings more than 25 years of pharmaceutical industry experience to his role. Prior to joining Mayne Pharma, Mr Cross was Head of Marketing for Hospira Inc., a leading global provider of pharmaceuticals and medical devices, where he was responsible for expansion of the new product portfolio and onmarket product growth across all markets in the region. Prior to joining Hospira, Mr Cross worked for six years with Mayne Pharma Limited in Europe and Australia and eight years with F H Faulding Co across strategy, business developmentMA, sales and marketing, HR and financeIT. since 2017.
| Age | 50 |
| Tenure | 7 years |
| Phone | 61 8 8209 2666 |
| Web | https://www.maynepharma.com |
Mayne Pharma Management Efficiency
The company has return on total asset (ROA) of (0.0328) % which means that it has lost $0.0328 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4124) %, meaning that it generated substantial loss on money invested by shareholders. Mayne Pharma's management efficiency ratios could be used to measure how well Mayne Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Kathryn Metcalfe | Bristol Myers Squibb | 50 | |
| Michael Nally | Merck Company | 44 | |
| Paul Autenried | Bristol Myers Squibb | 59 | |
| Joseph Eid | Bristol Myers Squibb | 52 | |
| Peter Fasolo | Johnson Johnson | 61 | |
| Jonathan Graham | Amgen Inc | 63 | |
| Julie Gerberding | Merck Company | 64 | |
| Azita SalekiGerhardt | AbbVie Inc | 61 | |
| Robert Davis | Merck Company | 54 | |
| Steven Mizell | Merck Company | 60 | |
| Sandra Leung | Bristol Myers Squibb | 60 | |
| Cristal Downing | Merck Company | 55 | |
| Jyoti Mehra | Gilead Sciences | 48 | |
| Roger Perlmutter | Merck Company | 67 | |
| Christopher Boerner | Bristol Myers Squibb | 53 | |
| Brian Durkin | AbbVie Inc | 60 | |
| Adam Dubow | Bristol Myers Squibb | 53 | |
| Kathryn Wengel | Johnson Johnson | 58 | |
| Jennifer Zachary | Merck Company | 46 | |
| Caroline Litchfield | Merck Company | 55 | |
| Andrew Dickinson | Gilead Sciences | 54 | |
Management Performance
| Return On Equity | -0.41 | |||
| Return On Asset | -0.0328 |
Mayne Pharma Group Leadership Team
Elected by the shareholders, the Mayne Pharma's board of directors comprises two types of representatives: Mayne Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mayne. The board's role is to monitor Mayne Pharma's management team and ensure that shareholders' interests are well served. Mayne Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mayne Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kimberly JD, Exec Counsel | ||
| Shawn BSc, MD CEO | ||
| Hemanshu Pandya, VP Division | ||
| Daniel Moore, Ex Solutions | ||
| Aaron Gray, Chief Officer | ||
| Stefan Cross, President of Mayne Pharma USA | ||
| Brant Schofield, Exec Devel | ||
| Lisa Pendlebury, Investor Relations Manager | ||
| Gerard MD, Chief Officer | ||
| Andrew Herdman, Vice President Group Human Resources |
Mayne Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Mayne Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.41 | |||
| Return On Asset | -0.0328 | |||
| Profit Margin | (0.62) % | |||
| Operating Margin | (0.17) % | |||
| Current Valuation | 448.85 M | |||
| Shares Outstanding | 1.74 B | |||
| Shares Owned By Insiders | 22.62 % | |||
| Shares Owned By Institutions | 18.64 % | |||
| Price To Earning | 11.25 X | |||
| Price To Book | 0.73 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Mayne Pink Sheet
Mayne Pharma financial ratios help investors to determine whether Mayne Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mayne with respect to the benefits of owning Mayne Pharma security.